Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZURA Stock Forecast 2025-2026
$1.14
Current Price
$70.23M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ZURA Price Targets
+2,180.7%
To High Target of $26.00
+1,040.4%
To Median Target of $13.00
+163.2%
To Low Target of $3.00
ZURA Price Momentum
-6.6%
1 Week Change
+5.6%
1 Month Change
-66.3%
1 Year Change
-54.4%
Year-to-Date Change
-77.5%
From 52W High of $5.07
+17.5%
From 52W Low of $0.97
📊 TOP ANALYST CALLS
Did ZURA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Zura Bio is one of their latest high-conviction picks.
Latest ZURA Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, ZURA has a bullish consensus with a median price target of $13.00 (ranging from $3.00 to $26.00). Currently trading at $1.14, the median forecast implies a 1,040.4% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 2,180.7% upside. Conversely, the most conservative target is provided by Mitchell Kapoor at HC Wainwright & Co., suggesting a 163.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZURA Analyst Ratings
6
Buy
1
Hold
0
Sell
ZURA Price Target Range
Low
$3.00
Average
$13.00
High
$26.00
Current: $1.14
Latest ZURA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZURA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $17.00 |
| Apr 3, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Maintains | $3.00 |
| Mar 26, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $19.00 |
| Mar 26, 2025 | Chardan Capital | Matthew Barcus | Buy | Maintains | $10.00 |
| Mar 26, 2025 | Guggenheim | Yatin Suneja | Buy | Reiterates | $15.00 |
| Dec 24, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Dec 11, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $0.00 | |
| Nov 18, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Nov 9, 2024 | Chardan Capital | Buy | Maintains | $0.00 | |
| Nov 8, 2024 | Chardan Capital | Matthew Barcus | Buy | Maintains | $12.00 |
| Nov 4, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $15.00 |
| Oct 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Oct 18, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
| Sep 19, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $26.00 |
| Sep 5, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Initiates | $5.00 |
| Aug 15, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
| Jun 17, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
| Jun 12, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Initiates | $0.00 |
| May 10, 2024 | Oppenheimer | Jeff Jones | Outperform | Maintains | $21.00 |
Zura Bio Ltd. (ZURA) Competitors
The following stocks are similar to Zura Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zura Bio Ltd. (ZURA) Financial Data
Zura Bio Ltd. has a market capitalization of $70.23M with a P/E ratio of 7.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -55.0%.
Valuation Metrics
Market Cap
$70.23M
Enterprise Value
$-86,827,504
P/E Ratio
7.9x
PEG Ratio
-1.5x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+241.8%
Current Ratio
8.1x
Debt/Equity
0.0x
ROE
-55.0%
ROA
-31.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zura Bio Ltd. (ZURA) Business Model
About Zura Bio Ltd.
What They Do
Develops innovative therapeutics for immune disorders.
Business Model
Zura Bio Ltd. generates revenue through the research and development of therapeutics aimed at treating immune disorders and other critical diseases. The company focuses on creating drugs and treatment protocols that enhance patient outcomes, particularly in areas with limited treatment options, thus positioning itself for potential partnerships and sales to healthcare providers and pharmaceutical companies.
Additional Information
Zura Bio's contributions are significant in the pharmaceutical and healthcare industries, attracting investor interest due to its potential for groundbreaking advancements in the biopharma sector. The company's innovation may also impact related sectors, such as healthcare equipment and supply chain management, by increasing demand for associated medical services and products.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
30
CEO
Mr. Robert Lisicki
Country
United States
IPO Year
2023
Website
zurabio.comZura Bio Ltd. (ZURA) Latest News & Analysis
Latest News
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) will present a corporate overview at the Jefferies Global Healthcare Conference on June 4, 2025, focusing on its dual-pathway antibodies for autoimmune diseases.
Why It Matters
Zura Bio's presentation at a prominent healthcare conference signals potential investor interest and visibility, which could impact stock performance and market sentiment regarding its pipeline.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio has initiated a Phase 2 study for TibuSHIELD, testing tibulizumab in adults with hidradenitis suppurativa.
Why It Matters
Zura Bio's launch of a Phase 2 study for tibulizumab could signal potential revenue growth and market expansion, influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) reported steady progress in Q1 2025, focusing on dual-pathway antibodies for autoimmune diseases. Financial results were shared alongside corporate updates.
Why It Matters
Zura Bio’s positive financial results and progress in clinical development may indicate potential growth and value appreciation, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) reported its 2024 financial results, highlighting key milestones in leadership expansion and clinical pipeline advancements in immunology and autoimmune diseases.
Why It Matters
Zura Bio's financial results and milestone achievements signal growth potential in the biotech sector, which can influence stock performance and investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) will participate in the Leerink Partners Global Healthcare Conference on March 11, 2025, and will hold investor meetings in Miami, FL. A live webcast will be available.
Why It Matters
Zura Bio's participation in a major healthcare conference and investor meetings signals potential growth opportunities and insights into its drug development, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)
4 months ago
Quick Summary
Zura Bio Limited (ZURA) is technically oversold, suggesting reduced selling pressure. Analysts are revising earnings estimates higher, indicating a potential trend reversal.
Why It Matters
Zura Bio Limited's oversold status and analysts' upgraded earnings estimates suggest a potential price rebound, making it a stock to watch for recovery and investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ZURA Stock
What is Zura Bio Ltd.'s (ZURA) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Zura Bio Ltd. (ZURA) has a median price target of $13.00. The highest price target is $26.00 and the lowest is $3.00.
Is ZURA stock a good investment in 2025?
According to current analyst ratings, ZURA has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZURA stock?
Wall Street analysts predict ZURA stock could reach $13.00 in the next 12 months. This represents a 1,040.4% increase from the current price of $1.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zura Bio Ltd.'s business model?
Zura Bio Ltd. generates revenue through the research and development of therapeutics aimed at treating immune disorders and other critical diseases. The company focuses on creating drugs and treatment protocols that enhance patient outcomes, particularly in areas with limited treatment options, thus positioning itself for potential partnerships and sales to healthcare providers and pharmaceutical companies.
What is the highest forecasted price for ZURA Zura Bio Ltd.?
The highest price target for ZURA is $26.00 from Yasmeen Rahimi at Piper Sandler, which represents a 2,180.7% increase from the current price of $1.14.
What is the lowest forecasted price for ZURA Zura Bio Ltd.?
The lowest price target for ZURA is $3.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a 163.2% increase from the current price of $1.14.
What is the overall ZURA consensus from analysts for Zura Bio Ltd.?
The overall analyst consensus for ZURA is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are ZURA stock price projections?
Stock price projections, including those for Zura Bio Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 18, 2025 7:07 PM UTC